Clinical Trial: NCT05305365
Study Assessing QBS72S For Treating Brain Metastases
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Melanie Hayden Gephart |
| Information Provided By: | Stanford University |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Official Title
Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Conditions
Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Intervention / Treatment
- Drug: QBS72S
Other Study ID Numbers
- IRB-63041
- NCI-2023-00648
Start Date (Actual)
2022-08-16
Primary Completion Date (Actual)
2025-06-20
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
21
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Melanie Hayden Gephart |
| Information Provided By: | Stanford University |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Official Title
Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Conditions
Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Intervention / Treatment
- Drug: QBS72S
Other Study ID Numbers
- IRB-63041
- NCI-2023-00648
Start Date (Actual)
2022-08-16
Primary Completion Date (Actual)
2025-06-20
Study Completion Date (Estimated)
2027-12
Enrollment (Actual)
21
Study Type
Interventional
Phase
Phase 2